Therapy for most common cause of cystic fibrosis safe and effective in 6-11
An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the ...
Mar 18, 2021
0
3